$REGN

Analysts Eve Burstein (Bernstein) and Chris Schott (J.P. Morgan) maintained Buy ratings on Agilent (A) and Regeneron (REGN) with price targets of $180 and $900, respectively. Agilent's consensus target is $177.87 (3.4% upside), while Regeneron's is $843.47 (4.9% upside). Both stocks have Strong Buy/Moderate Buy consensus ratings.

Regeneron (REGN) expects low- to mid-teens percentage growth for EYLEA HD in Q3 and Q4, despite biosimilar competition. Dupixent sales are annualizing at $24B, with strong growth outside atopic dermatitis. Libtayo sales rose over 30% YoY. The company anticipates several pipeline readouts, including data on cemdisiran in generalized myasthenia gravis and paroxysmal nocturnal hemoglobinuria. Regeneron also plans to bring four novel targets into the clinic this year.

Regeneron (REGN) and Sanofi (SNYNF) completed a long-term safety extension trial for itepekimab in COPD patients. The double-blind study evaluated the drug's safety and tolerability over 72 weeks. The trial's completion and positive results could reduce perceived risks, support a COPD launch, and enhance the companies' revenue outlook in respiratory care.

Dupilumab reduced moderate/severe COPD exacerbations across all seasons, with the largest reductions in summer and spring. Data from phase 3 trials showed a 31% decrease in exacerbation rate vs. placebo. According to researchers, dupilumab's efficacy is consistent year-round, providing clinicians with further confidence in its use for eligible COPD patients.

Regeneron highlighted growth in Dupixent's respiratory and dermatology indications, with COPD and chronic spontaneous urticaria showing strong performance. The company discussed its immunology and inflammation pipeline, including long-acting antibodies and bispecific candidates. Regeneron also mentioned ongoing discussions with Sanofi about the future of their collaboration on Dupixent. The company expects an FDA decision on cemdisiran for myasthenia gravis in November and Phase III readouts for

Analysts estimate a 70% probability that Sanofi and Regeneron will secure a two-year U.S. patent extension for Dupixent, potentially extending exclusivity to 2033. HSBC raised its price target for Regeneron to $920, maintaining a Buy rating.

An Alabama child received Otarmeni, a newly FDA-approved gene therapy for a rare form of inherited deafness, at Boston Children’s Hospital. Regeneron Pharmaceuticals manufactures the treatment, which targets OTOF gene mutations. The therapy is provided at no cost to eligible patients, though related medical costs may apply. The ALL Kids program, administered by the Alabama Department of Public Health, facilitated access to the treatment.

Regeneron Pharmaceuticals (REGN) and certain officers face a securities class action lawsuit over alleged misleading statements about the Phase III Fianlimab-Libtayo study. Investors claim the trial's statistical assumptions were flawed and the study may not meet its primary endpoint. The lawsuit and a Libtayo recall could lead to higher legal costs, regulatory scrutiny, and potential impact on the company's pipeline and financial profile. REGN has a market value of about $80.6 billion.

Regeneron Pharmaceuticals Inc. (REGN) shares fell 1.78% to $793.26 on Thursday, extending a five-day losing streak. This underperformed broader market declines, with the S&P 500 and Dow Jones down 0.58% and 0.60%, respectively.

American Century Investments sold Regeneron (REGN) due to slow commercialization of its macular degeneration treatment. The fund cited limited appreciation potential. REGN closed at $810.31, with a $83.43B market cap, and a 52-week gain of 43.84%. The fund's Q1 2026 return was 16.38%, slightly below the Russell 1000 Growth Index.